{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:00:19Z","timestamp":1792857619551,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03607-8","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T11:03:22Z","timestamp":1759921402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A meta-analysis based on propensity analysis studies comparing neoadjuvant immunochemotherapy and neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma"],"prefix":"10.1007","volume":"16","author":[{"given":"Zixian","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiani","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"3607_CR1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/gutjnl-2014-308124","volume":"64","author":"M Arnold","year":"2012","unstructured":"Arnold M, Soerjomataram I, Ferlay J, et al. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2012;64:381\u20137.","journal-title":"Gut"},{"key":"3607_CR2","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","volume":"134","author":"W Cao","year":"2020","unstructured":"Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in china: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2020;134:783\u201391.","journal-title":"Chin Med J (Engl)"},{"key":"3607_CR3","doi-asserted-by":"publisher","first-page":"100422","DOI":"10.1016\/j.eclinm.2020.100422","volume":"24","author":"HY Zhou","year":"2020","unstructured":"Zhou HY, Zheng SP, Li AL, et al. Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study). EClinicalMedicine. 2020;24:100422.","journal-title":"EClinicalMedicine"},{"key":"3607_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","volume":"34","author":"H Tang","year":"2023","unstructured":"Tang H, Wang H, Fang Y, et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Ann Oncol. 2023;34:163\u201372.","journal-title":"Ann Oncol"},{"key":"3607_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamasurg.2021.2373","volume":"156","author":"H Yang","year":"2021","unstructured":"Yang H, Liu H, Chen Y, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial. JAMA Surg. 2021;156:721\u20139.","journal-title":"JAMA Surg"},{"key":"3607_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","volume":"39","author":"BM Eyck","year":"2021","unstructured":"Eyck BM, van Lanschot JJB, Hulshof MCCM, et al. Ten-Year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39:1995\u20132004.","journal-title":"J Clin Oncol"},{"key":"3607_CR7","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, Machida R, Ito Y, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3. Trial Lancet. 2024;404:55\u201366.","journal-title":"Trial Lancet"},{"key":"3607_CR8","doi-asserted-by":"publisher","first-page":"9097","DOI":"10.1038\/s41467-024-52977-0","volume":"15","author":"Z Yang","year":"2024","unstructured":"Yang Z, Tian H, Chen X, et al. Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma. Nat Commun. 2024;15:9097.","journal-title":"Nat Commun"},{"key":"3607_CR9","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/1759-7714.15291","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Li H, Yu B, et al. Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: data from literature review and a real-world analysis. Thorac Cancer. 2024;15:1072\u201381.","journal-title":"Thorac Cancer"},{"key":"3607_CR10","first-page":"e250220","volume":"19","author":"X Guo","year":"2025","unstructured":"Guo X, Chen C, Zhao J, et al. Neoadjuvant chemoradiotherapy vs chemoimmunotherapy for esophageal squamous cell carcinoma. JAMA Surg. 2025;19:e250220.","journal-title":"JAMA Surg"},{"key":"3607_CR11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jtcvs.2023.12.030","volume":"168","author":"YK Yu","year":"2024","unstructured":"Yu YK, Meng FY, Wei XF, et al. Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2024;168:417\u2013e4283.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3607_CR12","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.","journal-title":"Int J Surg"},{"key":"3607_CR13","volume-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"G Wells","year":"2020","unstructured":"Wells G, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [Internet]: Ottawa Hospital Research Institute; 2020."},{"key":"3607_CR14","doi-asserted-by":"publisher","first-page":"836338","DOI":"10.3389\/fimmu.2022.836338","volume":"13","author":"ZN Hong","year":"2022","unstructured":"Hong ZN, Gao L, Weng K, et al. Safety and feasibility of esophagectomy following combined immunotherapy and chemotherapy for locally advanced esophageal squamous cell carcinoma: A propensity score. Matching Anal Front Immunol. 2022;13:836338.","journal-title":"Matching Anal Front Immunol"},{"key":"3607_CR15","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.2147\/JIR.S424454","volume":"16","author":"J Zhao","year":"2023","unstructured":"Zhao J, Hao S, Tian J, et al. Comparison of neoadjuvant immunotherapy plus chemotherapy versus neoadjuvant chemoradiotherapy for patients with esophageal squamous cell carcinoma: A propensity score matching study. J Inflamm Res. 2023;16:3351\u201363.","journal-title":"J Inflamm Res"},{"key":"3607_CR16","doi-asserted-by":"publisher","first-page":"e70113","DOI":"10.1002\/cam4.70113","volume":"13","author":"X Duan","year":"2024","unstructured":"Duan X, Zhao F, Shang X, et al. Neoadjuvant chemoimmunotherapy was associated with better short-term survival of patients with locally advanced esophageal squamous cell carcinoma compared to neoadjuvant. Chemoradiotherapy Cancer Med. 2024;13:e70113.","journal-title":"Chemoradiotherapy Cancer Med"},{"key":"3607_CR17","doi-asserted-by":"publisher","first-page":"1052542","DOI":"10.3389\/fimmu.2022.1052542","volume":"13","author":"L Xu","year":"2022","unstructured":"Xu L, Wei XF, Li CJ, et al. Pathologic responses and surgical outcomes after neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. Front Immunol. 2022;13:1052542.","journal-title":"Front Immunol"},{"key":"3607_CR18","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1186\/s12885-024-12946-8","volume":"24","author":"Y Wang","year":"2024","unstructured":"Wang Y, Ma K, Zhang H, et al. Comparison of pathologic response and survival outcomes between neoadjuvant chemoradiotherapy (nCRT) and neoadjuvant immunochemotherapy (nICT) in patients with locally advanced esophageal squamous cell carcinoma: a propensity score-matched analysis. BMC Cancer. 2024;24:1228.","journal-title":"BMC Cancer"},{"key":"3607_CR19","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1245\/s10434-023-14534-9","volume":"31","author":"Y Tian","year":"2024","unstructured":"Tian Y, Shi Z, Wang C, et al. A comparison of clinicopathologic outcomes and patterns of lymphatic spread across neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, and neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma. Ann Surg Oncol. 2024;31:860\u201371.","journal-title":"Ann Surg Oncol"},{"key":"3607_CR20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jtcvs.2024.06.020","volume":"169","author":"X Yang","year":"2025","unstructured":"Yang X, Yin H, Zhang S, et al. Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg. 2025;169:289\u2013e3006.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"3607_CR21","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.21037\/jtd-2024-2107","volume":"17","author":"S Shi","year":"2025","unstructured":"Shi S, Li L, Zhou H, et al. Comparison of neoadjuvant chemotherapy plus immunotherapy versus chemoradiotherapy for esophageal squamous cell carcinoma patients: efficacy and safety outcomes. J Thorac Dis. 2025;17:2937\u201346.","journal-title":"J Thorac Dis"},{"key":"3607_CR22","first-page":"109383","volume":"183","author":"K Shao","year":"2025","unstructured":"Shao K, Du Y, Xu L, et al. Outcomes of neoadjuvant immunochemotherapy and neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous. Cell Carcinoma Surg. 2025;183:109383.","journal-title":"Cell Carcinoma Surg"},{"key":"3607_CR23","doi-asserted-by":"publisher","first-page":"7461","DOI":"10.1245\/s10434-023-13778-9","volume":"30","author":"F Su","year":"2023","unstructured":"Su F, Yang X, Yin J, et al. Validity of using pathological response as a surrogate for overall survival in neoadjuvant studies for esophageal cancer: A systematic review and Meta-analysis. Ann Surg Oncol. 2023;30:7461\u201371.","journal-title":"Ann Surg Oncol"},{"key":"3607_CR24","doi-asserted-by":"crossref","unstructured":"Conforti F, Pala L, Sala I et al. (2021) Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis BMJ 375:e066381.","DOI":"10.1136\/bmj-2021-066381"},{"key":"3607_CR25","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.jtho.2024.03.010","volume":"19","author":"JB Hines","year":"2024","unstructured":"Hines JB, Cameron RB, Esposito A, et al. Evaluation of major pathologic response and pathologic complete response as surrogate end points for survival in randomized controlled trials of neoadjuvant immune checkpoint Blockade in resectable in NSCLC. J Thorac Oncol. 2024;19:1108\u201316.","journal-title":"J Thorac Oncol"},{"key":"3607_CR26","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost KE, Satpathy AT, Wells DK, et al. Clonal replacement of tumor-specific T cells following PD-1 Blockade. Nat Med. 2019;25:1251\u20139.","journal-title":"Nat Med"},{"key":"3607_CR27","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.21037\/jtd-24-828","volume":"16","author":"L Liu","year":"2024","unstructured":"Liu L, Liu Y, Xu L, et al. Tumor immune microenvironment remodeling and prognosis of patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy with and without immunotherapy: a retrospective cohort study. J Thorac Dis. 2024;16:3909\u201322.","journal-title":"J Thorac Dis"},{"key":"3607_CR28","doi-asserted-by":"publisher","first-page":"1312380","DOI":"10.3389\/fimmu.2024.1312380","volume":"15","author":"Z Yehan","year":"2024","unstructured":"Yehan Z, Sheng Q, Hong Y, et al. To develop a prognostic model for neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma by analyzing the immune microenvironment. Front Immunol. 2024;15:1312380.","journal-title":"Front Immunol"},{"key":"3607_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12885-024-11886-7","volume":"24","author":"RD Lu","year":"2024","unstructured":"Lu RD, Wei ZD, Liu YX, et al. Increased resected lymph node stations improved survival of esophageal squamous cell carcinoma. BMC Cancer. 2024;24:177.","journal-title":"BMC Cancer"},{"key":"3607_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/JS9.0000000000001863","volume":"111","author":"K Li","year":"2025","unstructured":"Li K, Zhao J, Wei X, et al. Optimizing lymph node dissection can better for accurate assessment and management of lymph node recurrence in postoperative thoracic esophageal squamous cell carcinoma. Int J Surg. 2025;111:1\u20134.","journal-title":"Int J Surg"},{"key":"3607_CR31","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00432-024-05967-0","volume":"150","author":"H Zhou","year":"2024","unstructured":"Zhou H, Lin J, Wei W, et al. Frequency and distribution pattern of lymph node metastasis after neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2024;150:476.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3607_CR32","doi-asserted-by":"publisher","first-page":"821626","DOI":"10.3389\/fonc.2022.821626","volume":"12","author":"J Zheng","year":"2022","unstructured":"Zheng J, Huang B, Xiao L, et al. Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials. Front Oncol. 2022;12:821626.","journal-title":"Front Oncol"},{"key":"3607_CR33","doi-asserted-by":"publisher","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","volume":"92","author":"S Hussaini","year":"2021","unstructured":"Hussaini S, Chehade R, Boldt RG, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis. Cancer Treat Rev. 2021;92:102134.","journal-title":"Cancer Treat Rev"},{"key":"3607_CR34","doi-asserted-by":"crossref","unstructured":"Park R, Lopes L, Saeed A. Anti-PD-1\/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis. Clin Transl Onco 23:100\u20139.","DOI":"10.1007\/s12094-020-02397-5"},{"key":"3607_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/mco.2024.2798","volume":"22","author":"Z Su","year":"2024","unstructured":"Su Z, Guan M, Zhang L, et al. Factors associated with immune\u2013related severe adverse events (Review). Mol Clin Oncol. 2024;22:3.","journal-title":"Mol Clin Oncol"},{"key":"3607_CR36","first-page":"2162","volume":"37","author":"J Cho","year":"2019","unstructured":"Cho J, Kim HS, Ku BM, et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase. II Trial JCO. 2019;37:2162\u201370.","journal-title":"II Trial JCO"},{"key":"3607_CR37","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","volume":"19","author":"G Giaccone","year":"2018","unstructured":"Giaccone G, Kim C, Thompson J, et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2. Study Lancet Oncol. 2018;19:347\u201355.","journal-title":"Study Lancet Oncol"},{"key":"3607_CR38","doi-asserted-by":"publisher","first-page":"e20106","DOI":"10.1200\/JCO.2016.34.15_suppl.e20106","volume":"34","author":"A Rajan","year":"2016","unstructured":"Rajan A, Heery CR, Perry S, et al. Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETS). J Clin Oncol. 2016;34:e20106.","journal-title":"J Clin Oncol"},{"key":"3607_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-015-0081-1","volume":"3","author":"AA Tarhini","year":"2015","unstructured":"Tarhini AA, Zahoor H, Lin Y, et aL. Baseline Circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3:39.","journal-title":"J Immunother Cancer"},{"key":"3607_CR40","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1200\/jco.2011.29.15_suppl.2505","volume":"29","author":"MK Callahan","year":"2011","unstructured":"Callahan MK, Yang A, Tandon S, et al. Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. J Clin Oncol. 2011;29:2505.","journal-title":"J Clin Oncol"},{"key":"3607_CR41","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12967-018-1467-x","volume":"16","author":"S Valpione","year":"2018","unstructured":"Valpione S, Pasquali S, Campana LG, et al. Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 Blockade. J Transl Med. 2018;16:94.","journal-title":"J Transl Med"},{"key":"3607_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00262-020-02663-z","volume":"70","author":"Y Guzman-Prado","year":"2021","unstructured":"Guzman-Prado Y, Ben Shimol J, Samson O. Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis. Cancer Immunol Immunother. 2021;70:89\u2013100.","journal-title":"Cancer Immunol Immunother"},{"key":"3607_CR43","first-page":"476","volume":"58","author":"LC Cappelli","year":"2019","unstructured":"Cappelli LC, Dorak MT, Bettinotti MP, et al. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced. Inflamm Arthritis Rheumatol. 2019;58:476\u201380.","journal-title":"Inflamm Arthritis Rheumatol"},{"key":"3607_CR44","first-page":"897","volume":"68","author":"V Chat","year":"2019","unstructured":"Chat V, Ferguson R, Simpson D, et al. Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint Inhibition cancer immunology. Immunotherapy. 2019;68:897\u2013905.","journal-title":"Immunotherapy"},{"key":"3607_CR45","doi-asserted-by":"publisher","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","volume":"9","author":"R Julie","year":"2021","unstructured":"Julie R, Brahmer H, Abu-Sbeih P, Antonio, Ascierto, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9:e002435.","journal-title":"J Immunother Cancer"},{"key":"3607_CR46","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1097\/JS9.0000000000000487","volume":"109","author":"Z Hong","year":"2023","unstructured":"Hong Z, Xu J, Chen Z, et al. Additional neoadjuvant immunotherapy does not increase the risk of anastomotic leakage after esophagectomy for esophageal squamous cell carcinoma: a multicenter retrospective cohort study. Int J Surg. 2023;109:2168\u201378.","journal-title":"Int J Surg"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03607-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03607-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03607-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:04:05Z","timestamp":1759925045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03607-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3607"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03607-8","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1833"}}